Correlating Ki67 and other prognostic markers with Oncotype DX recurrence score in early estrogen receptor-positive breast cancer.
Aaron C TanBob T LiKazi NaharSuzanne DanielettoEva S FongTrevor CurrerAndrew ParasynPhilip MiddletonHeidi WongDenis SmartJosie J RutovitzPhilip McCloudT Michael HughesGavin M MarxPublished in: Asia-Pacific journal of clinical oncology (2017)
Ki67 and conventional prognostic markers do not correlate with Oncotype DX RS. In the setting where conventional prognostic markers do not show a clear indication for or against adjuvant chemotherapy as determined by consensus in a multidisciplinary team, Ki67 is not a substitute for Oncotype DX testing. RS may provide additional information to aid decision making for adjuvant chemotherapy.